CAJ | 학술논문

目的：探讨克唑替尼治疗中国 ALK 融合基因阳性的非小细胞肺癌（NSCLC）患者的疗效和安全性。方法14名患者接受至少4周的克唑替尼（250 mg，q12h）治疗，以评价治疗后的近期疗效、生活质量、不良反应。结果12例患者口服克唑替尼治疗后，11例（91.67%）获得部分缓解，1例（8.33%）获得疾病稳定，客观缓解率为91.67%；在生活质量评估中，患者的疲乏、气短、睡眠等均得到改善；不良反应主要为消化道症状，其次是谷丙转氨酶升高（64.29%），视觉障碍（57.14%），大部分为1～2级。结论克唑替尼作为 ALK 融合基因阳性的 NSCLC 患者的靶向治疗，具有良好的疗效及安全性，不良反应轻微。
목적：탐토극서체니치료중국 ALK 융합기인양성적비소세포폐암（NSCLC）환자적료효화안전성。방법14명환자접수지소4주적극서체니（250 mg，q12h）치료，이평개치료후적근기료효、생활질량、불량반응。결과12례환자구복극서체니치료후，11례（91.67%）획득부분완해，1례（8.33%）획득질병은정，객관완해솔위91.67%；재생활질량평고중，환자적피핍、기단、수면등균득도개선；불량반응주요위소화도증상，기차시곡병전안매승고（64.29%），시각장애（57.14%），대부분위1～2급。결론극서체니작위 ALK 융합기인양성적 NSCLC 환자적파향치료，구유량호적료효급안전성，불량반응경미。
Objective To make a summary of efficacy and tolerability of crizotinib in Chinese EML4-ALK-posi-tive NSCLC patient. Method 14 NSCLC patients with positive ALK fusion gene were administered with crizotinib (250 mg, q12h) for at least 4 weeks, in which the efficacy and tolerability of crizotinib were evaluated. Result Among the 12 patients who were included in final analysis, 11 patients achieved partial remission (PR), one patient was with stable disease (SD, 8.33%). A statistically significant (P<0.05) and clinically meaningful (≥10 points) im-provement from baseline was observed for patient-reported dyspnea, fatigue and global QOL. The most frequent ad-verse reactions were gastrointestinal disorders, elevated ALT (64.29% ), visual disorder (57.14% ), and which were mostly in grade 1-2. Conclusion As a target therapy for NSCLC, crizotinib demonstrates a high response rate, favor-able tolerability profile and significant improvement in patient-reported symptoms.